An FDA-approved blood sugar-lowering medicine may assist prevent vascular constraint and stiffness in aged male mice.
The study shows that the medication stopped the constriction and stiffening of the blood vessels
According to new research published in GeroScience by the University of Missouri School of Medicine, an FDA-approved medicine utilized to control blood glucose in people with Type 2 diabetes may help in reducing blood vessel dysfunction connected with aging.
Camila Manrique-Acevedo, MD, associate professor of medication at the University of Missouri.
Researchers initially examined the impact of aging on human blood artery function and stiffness. The scientists then looked at how the sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin (Empa) impacted blood vessel function and arterial stiffness in senior male mice.
” Cardiovascular illness is the main cause of death in older adults in the U.S.,” said Camila Manrique-Acevedo, MD, associate teacher of medicine. “Weight loss, physical activity, antihypertensive therapy, and lipid-lowering drugs have actually revealed variable efficiency at enhancing blood vessel function and minimizing arterial stiffness. However extra techniques are needed to enhance vascular health in older grownups.”
“Weight loss, physical activity, antihypertensive treatment, and lipid-lowering drugs have actually shown variable efficiency at improving blood vessel function and lowering arterial stiffness. Extra methods are needed to enhance vascular health in older grownups.”
In order to examine the impacts of Empa on vascular aging, 72-week-old male mice were divided into 2 groups. After evaluating both groups six weeks later on, researchers found the mice treated with Empa experienced improved blood vessel function, decreased arterial stiffness, and other vascular benefits.
The researchers initially compared capillary function and tightness in 18 healthy human clients with an average age of 25 to 18 patients with an average age of 61. When compared to the younger clients, the older patients displayed reduced endothelial function and increased aortic stiffness.
” Our findings in young and older grownups validate previous medical data demonstrating the effect of aging on capillary function and arterial tightness,” Manrique-Acevedo said. “Importantly, we were able to duplicate this information in a rodent design.”
In order to examine the effects of Empa on vascular aging, 72-week-old male mice were divided into 2 groups. Twenty-nine were fed for six weeks with a diet enriched with Empa, while the other half were provided basic food. After examining both groups 6 weeks later, researchers found the mice treated with Empa experienced improved capillary function, decreased arterial stiffness, and other vascular benefits.
” To our knowledge, this is the very first study to examine the prospective role of SGLT2 inhibition in reversing vascular aging,” Manrique-Acevedo said. “And our findings highlight the requirement for more medical examinations to figure out the prospective function of SGLT2 inhibition as a restorative tool to postpone or reverse vascular aging in humans.”
Part of the assistance for this study was provided by the National Institutes of Health and a VA Merit Grant. The material does not always represent the official views of the financing agency. The authors state no potential disputes of interest.
Referral: “SGLT2 inhibition attenuates arterial dysfunction and reduces vascular F-actin content and expression of proteins connected with oxidative stress in aged mice” by Rogerio N. Soares, Francisco I. Ramirez-Perez, Francisco J. Cabral-Amador, Mariana Morales-Quinones, Christopher A. Foote, Thaysa Ghiarone, Neekun Sharma, Gavin Power, James A. Smith, R. Scott Rector, Luis A. Martinez-Lemus, Jaume Padilla and Camila Manrique-Acevedo, 15 April 2022, GeroScience.DOI: 10.1007/ s11357-022-00563-x.
